Clinical trial
A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With Advanced, Unresectable Cervical Cancer With Disease Progression During or After Platinum-Containing Chemotherapy
NCT04246489 is registered in ClinicalTrials.gov with EMD Serono Research & Development Institute, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With Advanced, Unresectable Cervical Cancer With Disease Progression During or After Platinum-Containing Chemotherapy
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 30, 2020
- Completion date
- December 14, 2022
- Enrollment
- 146 (actual)
- Sites
- 73
Conditions
As the registry lists them; a condition with its own page is linked.